Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-066817

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stuart Shanler
Officer — Chief Scientific Officer
Period of report
Dec 15, 2017
Accepted (ET)
Dec 21, 2017 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Dec 15, 2017M1,300—A263,178D
Common StockDec 15, 2017F395$24.23D262,783D
Common StockF1Dec 18, 2017M1,450—A264,233D
Common StockDec 18, 2017F441$24.12D263,792D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitsF1,F3—Dec 15, 2017M1,300D——Common Stock1,3009,100D
Restricted Stock UnitsF1,F4—Dec 18, 2017M1,450D——Common Stock1,4502,900D

Explanation of responses